Fagan Associates Inc. grew its stake in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 8.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,610 shares of the medical research company’s stock after purchasing an additional 1,370 shares during the quarter. Fagan Associates Inc.’s holdings in PRA Health Sciences were worth $1,940,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Wellington Shields Capital Management LLC bought a new position in shares of PRA Health Sciences during the third quarter valued at approximately $551,000. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of PRA Health Sciences by 46.3% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 57,800 shares of the medical research company’s stock valued at $6,369,000 after purchasing an additional 18,300 shares during the last quarter. Dupont Capital Management Corp grew its holdings in shares of PRA Health Sciences by 589.8% during the third quarter. Dupont Capital Management Corp now owns 24,900 shares of the medical research company’s stock valued at $2,744,000 after purchasing an additional 21,290 shares during the last quarter. Penserra Capital Management LLC bought a new position in shares of PRA Health Sciences during the third quarter valued at approximately $5,884,000. Finally, Lisanti Capital Growth LLC bought a new position in shares of PRA Health Sciences during the third quarter valued at approximately $612,000. 98.82% of the stock is owned by institutional investors.
Shares of NASDAQ PRAH opened at $106.43 on Friday. The company has a debt-to-equity ratio of 1.22, a current ratio of 0.89 and a quick ratio of 0.93. The company has a market cap of $6.89 billion, a PE ratio of 28.15, a price-to-earnings-growth ratio of 1.54 and a beta of 0.73. PRA Health Sciences Inc has a 12-month low of $76.39 and a 12-month high of $112.88.
PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, October 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.07 by $0.06. The business had revenue of $717.60 million during the quarter, compared to the consensus estimate of $729.63 million. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The business’s revenue was up 23.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.88 earnings per share. On average, analysts predict that PRA Health Sciences Inc will post 3.93 earnings per share for the current year.
Several research firms have recently commented on PRAH. KeyCorp reaffirmed a “buy” rating and set a $115.00 target price on shares of PRA Health Sciences in a report on Thursday, August 2nd. BidaskClub upgraded PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Jefferies Financial Group reiterated a “buy” rating and set a $115.00 price objective on shares of PRA Health Sciences in a research report on Friday, July 20th. Credit Suisse Group boosted their price objective on PRA Health Sciences from $104.00 to $107.00 and gave the stock an “outperform” rating in a research report on Thursday, August 2nd. Finally, SunTrust Banks boosted their price objective on PRA Health Sciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, August 3rd. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $111.50.
COPYRIGHT VIOLATION WARNING: “Fagan Associates Inc. Buys 1,370 Shares of PRA Health Sciences Inc (PRAH)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/11/fagan-associates-inc-buys-1370-shares-of-pra-health-sciences-inc-prah.html.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Further Reading: What is a conference call?
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.